Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°£¿Ü´ãµµ¾Ï¿¡¼­ P53 ¹ßÇöÀÇ ÀÇÀÇ Significance of p53 Overexpression in Extrahepatic Bile Duct Cancer

´ëÇѾÏÇÐȸÁö 1993³â 25±Ç 6È£ p.873 ~ 877
¿À±Ôö, ±è¿ìÈ£, ¹Ú¿ëÇö,
¼Ò¼Ó »ó¼¼Á¤º¸
¿À±Ôö (  ) 
¼­¿ï´ëÇб³

±è¿ìÈ£ (  ) 
¼­¿ï´ëÇб³
¹Ú¿ëÇö (  ) 
¼­¿ï´ëÇб³

Abstract


We investigated overexpression of p53 and it clinical significance in a series of 37 extrahepatic bile duct cancer. Deparaffinized sections of formalin-fixed tumor tissue samples taken from patients during 5 year period from 1986 to 1990 were
immunostained for p53 protein, using mouse anti-human p53 protein monoclonal antibody(Novocastra Lab-NCL-DO7, IgG2b, 1 : 100). Immunohistochemically detected p53 overexperssion was found in 32.4%(twelve cases) of 37 resected extrahepatic bile
duct
tumors. No immunostaining was found in adjacent normal tissues. There was no difference between p53 negative group and p53 overexpression group in clinico-pathologic characteristics including sex, extent of disease, histologic and gross types,
location
of tumor. The patients were analysed for survival time according to the extent of disease and p53 positivity. Prognosis of p53 positive and p53 negative group did not show any significant difference. This study has shown that one third of
extrahepatic
bile duct cancers had immunohistochemically detectable p53 overexpression and in this study we have not found any evidence of clinical or prognostic significance of p53 overexpression in cancers of extrahepatic bile duct.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS